Company Snapshot: Anixa Biosciences, Inc.

ANIX
Last	Change	Volume	High	Low

Company Overview

Anixa, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Anixa is developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.  It is developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy.  It is also developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  Anixa also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at www.anixa.com.

Client News

1. Sep 19 2023 Anixa Biosciences Establishes Cancer Business Advisory Board
2. Aug 31 2023 Anixa Biosciences to Participate in September Investor Conferences
3. Aug 28 2023 Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial
4. Aug 14 2023 Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit
5. Aug 10 2023 Could Anixa Biosciences (NASDAQ:ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?